Gilead Sciences

California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni, though it's been making headlines more recently due to its experimental coronavirus treatment remdesivir.
F500-2020-140-Gilead-Sciences
Gilead Sciences/AP Images

Company Information

As of 5/23/2022
Country
U.S.
Headquarters
Foster City, Calif.
Industry
Pharmaceuticals
CEO
Daniel P. O'Day
Website
www.gilead.com
Company Type
Public
Ticker
GILD
Revenues ($M)
$27,305
Profits ($M)
$6,225
Market Value ($M)
$74,656.5
Employees
14,400
Market value as of March 31, 2022.

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)
493
EPS % Change (from 2020)
4830%
EPS % Change (5 year annual rate)
-13.1%
EPS % Change (10 year annual rate)
10.8%

Total Return

Total Return to Investors (2021)
29.8%
Total Return to Investors (5 year, annualized)
4%
Total Return to Investors (10 year, annualized)
16%

Key Financials (Last Fiscal Year)

($ Millions)
% change
Revenues ($M)
-
10%
Profits ($M)
-
-97.7%
Assets ($M)
$68,407
-
Total Stockholder Equity ($M)
$18,202
-

Profit Ratios

Profit as % of Revenues
0.5%
Profits as % of Assets
0.2%
Profits as % of Stockholder Equity
0.7%

Company Information

Impact Segment
-
Sector
-
Industry
-
CEO
-
Website
-
Employees
-
Company Type
-
Revenues ($M) (Last Fiscal Year)
-
Profits ($M) (Last Fiscal Year)
-
Market Value ($M)
-

Company Info

Industry
-
Location
-
Industry Ranking
-
Previous Industry Ranking
-
Previous Top 50 Ranking
-
Website
-
Overall Score
-

Key Attributes of Reputation

Innovation
-
People Management
-
Use of Corporate Assets
-
Social Responsibility
-
Quality of Management
-
Financial Soundness
-
Long-Term Investment Value
-
Quality of Products/Services
-
Global Competitiveness
-

Revenue, Net Income

Revenue past four quarters ($M)
-
Net Income past four quarters ($M)
-

Growth Rates and Ranks

Revenue 3 Yr Growth Rank
-
Revenue 3 Yr Annual Growth Rate
-
EPS 3 Yr Growth Rank
-
EPS 3 Yr Annual Growth Rate
-
Total Return 3 Yr Rank
-
Total Return 3 Yr Annual Rate
-
Beat S&P 500 (9.6%)
-
P/E Ratio
-
Lists ranking Gilead Sciences
RANK129
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE
Latest news for Gilead Sciences